Meyd-773

Triple‑negative breast cancer (TNBC) lacks expression of estrogen, progesterone, and HER2 receptors, limiting therapeutic options. Hyperactivation of the PI3K/AKT signaling axis is a frequent driver of TNBC progression and resistance to chemotherapy.

The crew settled into a rhythm:

A combinatorial library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was screened for PI3K inhibition. MEYD‑773 (chemical name: 6‑[(4‑fluorophenyl)amino]‑2‑(pyridin‑3‑yl)‑1,3‑thiazolo[5,4‑d]pyrimidine) was identified as the lead compound (IC₅₀ = 12 nM for p110α). Kinase selectivity was assessed against a 340‑kinase panel. Cellular activity was evaluated in a panel of breast cancer cell lines (MDA‑MB‑231, HCC‑1806, BT‑549, MCF‑7, and T‑47D). Apoptosis, cell‑cycle distribution, and downstream signaling were examined by flow cytometry, western blot, and phospho‑proteomics. Pharmacokinetics (PK) and tolerability were studied in CD‑1 mice. Antitumor efficacy was tested in orthotopic TNBC xenografts and patient‑derived xenograft (PDX) models. MEYD-773

The crew responded with a unified “Affirmative,” their visors flashing green as they each completed the final biometric verification. and HER2 receptors

At T‑00:03:00, Captain Kwon addressed the crew via the ship’s omnipresent holo‑array: MEYD-773